LRP、TOPO-II在非小细胞肺癌中的协同表达及其临床意义  

CO-EXPRESSION OF LRP AND TOPO-II IN NSCLC AND ITS CLINICAL SIGNFICANCE

作　　者：郑少江[1] 吴焕明[1] 王伟[1] 

机构地区：[1]华中科技大学同济医学院病理系,武汉430030

出　　处：《中国组织化学与细胞化学杂志》2004年第2期180-183,共4页Chinese Journal of Histochemistry and Cytochemistry

摘　　要：目的　探讨肺耐药蛋白 (lungresistanceprotein ,LRP)和DNA拓扑异构酶II (topoisomerase II ,TOPO II)在非小细胞肺癌 (non smallcelllungcancer,NSCLC)中的协同表达及其临床意义。方法　用SP免疫组化方法检测 6 2例术前均未进行化疗的NSCLC组织中LRP、TOPO II蛋白的表达情况。结果　在NSCLC中LRP、TOPO II蛋白表达的阳性率分别为 75 8% (47/6 2例 ) ;6 4 5 % (40 /6 2例 )。LRP蛋白表达与分化程度相关。TOPO II蛋白表达与分化程度、有无淋巴结转移相关。LRP与TOPO II协同表达与生存率相关。结论　应用免疫组织化学方法检测NSCLC中LRP、TOPO II的表达对肿瘤的化疗药物选择和预后判断具有显著的临床意义。? Objective To investigate the expression and the clinical relationship between LRP and TOPO-II in NSCLC. Method Immunohistochemical S-P method was used to examine the expression of LRPprotein andTOPO-II protein in 62 cases of NSCLC which had not been treated by chemotherapy before surgery. Result Of the 62 cases,the positive rates of LRP protein and TOPO-II proteinwere 75.8%(47/62) and 64.5%(40/62)respectively. The expression of LRP protein was correlated signficantly with the degree of the tumor cells. The expression of TOPO-II protein was correlated signficantly with the histological type and lymph node metastasis. The co-expression of LRP and TOPO-II was correlated with the survival rate. Conclusion The status of the expression of LRP and TOPO-II detected by immuohistochemistry is of clinical significance for chemotherapy and prognosis of NSCLC.

关 键 词：肺耐药蛋白 DNA拓扑异构酶Ⅱ 多药耐药性 非小细胞肺癌 免疫组织化学 

分 类 号：R734.2[医药卫生—肿瘤]